Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

FutureMIND Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery

Coordinator
Ruprecht-Karls-Universitaet Heidelberg, Germany
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.4m
Total cost
—
Partners
17 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312148

What the project is doing

In the project's own words, from its summary on CORDIS.

Neuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technoloNeuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technology, the field continues to face major hurdles in early detection, risk-adapted surgery, accurate tumour classification, and the development of effective personalized treatments, underscoring the urgent need for innovative solutions to improve patient outcomes.

Current advancements in computer science, particularly in artificial intelligence (AI), are revolutionizing medicine and offer unprecedented opportunities to improve areas that have historically seen limited progress, such as neuro-oncological care. However, critical gaps remain between technical innovations and their clinical application. Moreover, physicians often lack the technical background to fully utilize AI, while computer science developments may not always address clinical realities.

The FutureMIND Doctoral Network aims to bridge these divides and fill in the gap of holistic experts needed to advance AI-driven diagnostics and discovery in neuro-oncology. FutureMIND brings together leading researchers, clinicians and entrepreneurs from eight countries to train 14 Doctoral Candidates (DCs) across different disciplines and sectors. By the end of FutureMIND, the DCs will be equipped to advance digital medicine as a new clinical tool to tackle brain cancers, with foreseeable impact on thousands of patients.

Importantly, FutureMIND will prepare a new generation of European experts capable of addressing future challenges and of preparing the EU to sovereignly lead the digital transformation in neuro-oncology, paradigmatically for other areas of medical care.

Topics

Who is involved

OrganisationCityCountryRole
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyCoordinator
Brainlab SeMunchenGermanyAssociatedpartner
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
Friedrich-Alexander-Universitaet Erlangen-NuernbergErlangenGermanyParticipant
Heidelberg Epignostix GmbHHeidelbergGermanyAssociatedpartner
Johner Institut GmbHKonstanzGermanyAssociatedpartner
Cercare Medical ApsAarhus CDenmarkAssociatedpartner
Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos IiiMadridSpainParticipant
Universidad Autonoma De MadridMadridSpainAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Universitetet I OsloOsloNorwayParticipant
Karolinska InstitutetStockholmSwedenParticipant
Oxford Nanopore Technologies LtdOxfordUnited KingdomAssociatedpartner
Proteotype Diagnostics LtdCambridgeUnited KingdomAssociatedpartner
The Queen's University of BelfastBelfastUnited KingdomParticipant
The University of NottinghamNottinghamUnited KingdomParticipant
Invenio Imaging IncSanta ClaraUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI